
Cat. #162023
Melan-mu3 cell line
Cat. #: 162023
Availability: 8-10 weeks
Organism: Mouse
Tissue: Skin
Disease: Hermansky-Pudlak syndrome
Model: Immortalised non-cancerous cell lines
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Elena Sviderskaya
Institute: St. George's University London
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Melan-mu3 cell line
- Organism: Mouse
- Tissue: Skin
- Disease: Hermansky-Pudlak syndrome
- Morphology: Small, oval-fusiform
- Model: Immortalised non-cancerous cell lines
- Description: The melan-mu1, -mu2 and mu-3 cell lines are immortal melanocyte cell lines derived from neonatal muted (Mutedmu/mu) Ink4aArf -/-B6.CHMU/Le mice. These cell lines lack muted, a subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). BLOC-1 is involved in cargo sorting from early-endosomes towards lysosome related organelles, including melanosomes. Pathogenic variants in the human ortholog of muted cause a form of Hermansky-Pudlak syndrome (HPS), HPS-11. HPS is a group of disorders characterised by hypopigmentation, bleeding tendency and other variable symptoms. These cells are hypopigmented despite the expression of tyrosinase. These cells are a useful model for HPS and for the study of trafficking of cargoes towards lysosome-related organelles
- Application: Melanocyte cell biology
Applications
- Application: Melanocyte cell biology
Handling
- Growth medium: RPMI + FBS (10%) + TPA (200 nM) + cholera toxin (CT) (200 pM)
- Storage conditions: liquid N2
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)




